Skip to Content
AbbVie started 2021 strong, surpassing first-quarter earnings and revenue estimates. The Chicago-based pharmaceutical company saw a revenue increase in the first quarter from its primary breadwinner, Humira, in the U.S. The drug has faced steep competition globally from biosimilars, but AbbVie made up for it with increased sales from recently released plaque psoriasis drug Skyrizi and treatment for severe rheumatoid arthritis, Rinvoq. The two drugs made $2.3 billion just 12 months after being released. In 2019 AbbVie acquired Allergan for an eye-popping $63 billion and is now starting to reap the benefits. Allergan’s products, which includes Botox, made up almost 20% of AbbVie’s 2020 revenue.
Courtesy of AbbVie
Lists ranking AbbVie
World’s 25 Best Workplaces - 2021Companies on this year's list earned recognition b...READ MOREview in list
Global 500 - 2021Total revenue for the world’s biggest companies fe...READ MOREview in list
100 Best Large Workplaces for Millennials - 2021We surveyed tens of thousands of employees to crea...READ MOREview in list
Fortune 500 - 2021This year’s Fortune 500 marks the 67th running of ...READ MOREview in list
100 Best Companies to Work For - 2021Our 2021 list of the 100 best companies to work fo...READ MOREview in list
20 Best Workplaces in Biotechnology and Pharmaceuticals - 2021The best U.S. biotechnology and pharmaceutical com...READ MOREview in list
World’s Most Admired Companies - 2021After a year in which humanity leaned more heavily...READ MOREview in list